NCI Definition [1]:
A vaccine consisting of recombinant modified vaccinia Ankara (MVA) viral vector encoding mutated forms of the genes for the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) type 16 and the human cytokine interleukin-2 (hIL2), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, recombinant vaccinia viral vector RO5217790 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing HPV E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 have been implicated in the tumorigenesis of cervical carcinoma.

Tipapkinogene sovacivec has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tipapkinogene sovacivec, 1 is phase 1/phase 2 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for tipapkinogene sovacivec clinical trials.

Anal squamous cell carcinoma, cervical squamous cell carcinoma, and penile carcinoma are the most common diseases being investigated in tipapkinogene sovacivec clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tipapkinogene Sovacivec
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tipapkinogene sovacivec and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ro5217790, recombinant vaccinia viral vector ro5217790, hpv16 e6/e7-encoding mva vaccine tg4001, mva-hpv-il2, mva-hpv16e6/e7-il2, r3484, rg3484, tg 4001, tg-4001, tg4001
NCIT ID [1]:


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.